Improvements in the accuracy of HER2 signal quantification may give clinicians further information regarding HER2 expression status and potentially allow for improved precision with regard to therapeutic decisions especially in patients with HER2-low breast cancer. Here, ERBB2 is linked to breast carcinoma.